PCN72 ECONOMIC EVALUATION OF SUNITINIB VS. INTERFERON-A AND BEVACIZUMAB + INTERFERON-A IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (CCRM) – BRAZILIAN PRIVATE HEALTH SYSTEM PERSPECTIVE
Oncology medicine.medical_specialty Bevacizumab business.industry Sunitinib Health Policy Perspective (graphical) Public Health, Environmental and Occupational Health medicine.disease Interferon Renal cell carcinoma Internal medicine Economic evaluation medicine business health care economics and organizations medicine.drug